MANHASSET, N.Y.--(BUSINESS WIRE)--Building on its legacy as the global pioneer in bioelectronic medicine, The Feinstein Institutes for Medical Research, the research home of Northwell Health, today announced the appointment of Brian S. Kim, MD, MTR, as vice president and chief biotechnology officer at Northwell and head of intellectual asset management at the Feinstein Institutes. Dr. Kim will also serve as the inaugural Robin and Jack Ross Chair in Bioelectronic Medicine and Neuroimmunology and professor in the Institute of Bioelectronic Medicine.
A leading dermatologist and physician-scientist, Dr. Kim joins the Feinstein Institutes from the Icahn School of Medicine at Mount Sinai. He has authored more than 190 peer-reviewed publications in leading journals, including Cell, Nature, Science, New England Journal of Medicine and JAMA. He has been continuously funded by the National Institutes of Health since 2011 and leads the Allen Discovery Center for Neuroimmune Interactions, a $10 million multi-institutional center funded by Allen Family Philanthropies.
“Dr. Kim bridges medical research, clinical innovation and biotechnology entrepreneurship, and will innovate the field of bioelectronic medicine,” said Kevin J. Tracey, MD, president and CEO of the Feinstein Institutes and the Karches Family Distinguished Chair in Medical Research. “As our first chief biotechnology officer, he will accelerate discoveries from our labs into useful treatments that reach patients faster.”
Ad Statistics
Times Displayed: 22833
Times Visited: 59 Stay up to date with the latest training to fix, troubleshoot, and maintain your critical care devices. GE HealthCare offers multiple training formats to empower teams and expand knowledge, saving you time and money.
Dr. Kim’s research has led to significant clinical advances, including the design of pivotal clinical trials that resulted in two first-in-class U.S. Food and Drug Administration-approved treatments for atopic dermatitis and prurigo nodularis. As an inventor of itch-centered technologies and holder of multiple patents, he co-founded Alys Pharmaceuticals, a clinical-stage immuno-dermatology biotech company, as well as two additional biotech companies, Neurommune Therapeutics and Attu Therapeutics, where he also serves as chair of the scientific advisory board.
His contributions to medicine have been recognized with numerous prestigious awards, including the Marion B. Sulzberger Award, Stephen I. Katz Lectureship, Donald Y. M. Leung Award, American Skin Association Research Achievement Award in Discovery, and the Young Dermatologist Achievement Award from the International League of Dermatological Societies. Dr. Kim has also served on the editorial boards of several prominent journals, including the Journal of Allergy and Clinical Immunology, Journal of Immunology, eLife and Cell Reports Medicine.
